LEHI, Utah, June 25, 2025 (GLOBE NEWSWIRE) -- Nature’s Sunshine Products, Inc. (NASDAQ: NATR) (“Nature’s Sunshine” or the “Company”), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the launch of an underwritten secondary public offering of up to 2,854,607 shares of its common stock to be sold by Fosun Pharma USA, Inc (the “Selling Stockholder”). The Selling Stockholder will receive all of the net proceeds from the offering. Nature’s Sunshine is not selling any sha ...

SCOTTSDALE, AZ, June 20, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or the “Company”) today provided an update on the expected timing for the closing of its previously announced acquisition of Yerbaé Brands Corp. (TSX-V: YERB.U) (“Yerbaé”). Following the approval of the acquisition by a majority of its stockholders on June 12, 2025, the companies have been working to complete the final administrative steps for the transaction. While the closing was anticipated this week, the pr ...

Core Viewpoint - USANA Health Sciences (USNA) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on an upward trend in earnings estimates, which significantly influences stock prices [1][4]. Earnings Estimates and Stock Ratings - The Zacks rating system is primarily driven by changes in a company's earnings picture, with the Zacks Consensus Estimate tracking EPS estimates from sell-side analysts [2]. - The correlation between earnings estimate revisions and near-term stock price movements makes the Zacks rating system valuable for investors, as it provides a clearer picture than subjective Wall Street analyst ratings [3][7]. Institutional Investor Influence - Institutional investors play a role in the relationship between earnings estimates and stock prices, as they adjust their valuations based on these estimates, leading to significant stock transactions that affect price movements [5]. Business Improvement Indicators - Rising earnings estimates and the Zacks rating upgrade for USANA Health suggest an improvement in the company's underlying business, which could lead to increased stock prices as investors respond positively [6]. Earnings Estimate Revisions for USANA Health - For the fiscal year ending December 2025, USANA Health is expected to earn $2.61 per share, with no year-over-year change, but the Zacks Consensus Estimate has increased by 1.8% over the past three months [9]. Zacks Rank System Performance - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. - The upgrade of USANA Health to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [11].

Home Run! Adia Med of Winter Park's AHCA Triumph Brings Insurance-Covered Healing to PatientsJune 16, 2025 9:00 AM EDT | Source: Adia Nutrition Inc.Winter Park, Florida--(Newsfile Corp. - June 16, 2025) - Adia Nutrition, Inc. (OTCQB: ADIA), a leading innovator in regenerative medicine and nutritional supplements, is thrilled to announce that its state-of-the-art clinic, Adia Med of Winter Park, has received full approval from the Agency for Health Care Administration (AHCA). This milestone all ...

DENVER, June 12, 2025 (GLOBE NEWSWIRE) -- Mama Bird® is hatching at Sprouts this season! Mama Bird, maker of brain-boosting vitamins for families, is excited to announce that four of its best-selling prenatal and kids’ vitamins are now available at Sprouts Farmers Market for a limited time in stores nationwide. Created by neurologist Dr. Mika Gupta and inspired by her own parenting journey, Mama Bird is on a mission to support cognitive health from the very beginning — helping families feel confident they’ ...

LTH hits the summer flavor trifecta as spicy margarita, wild berry and strawberry lemonade join HYDRATE lineupCHANHASSEN, Minn., June 11, 2025 /PRNewswire/ -- Research shows millions or Americans are chronically dehydrated and as summer approaches and temperatures rise that number increases. To help with this, Life Time (NYSE: LTH) today announced three new flavors in the LTH HYDRATE electrolytes collection. Spicy Margarita, Wild Berry and Strawberry Lemonade join the original lineup of Peach Mango, Lemon-L ...

Summary of Niagen Bioscience Conference Call Company Overview - Niagen Bioscience is focused on the development and commercialization of nicotinamide riboside (Niagen), a molecule that elevates NAD levels in cells, which is crucial for energy metabolism and cellular repair [5][7][8] - The company has over 90 patents protecting its core molecule and has built a strong scientific foundation with extensive research [8][14] Core Points and Arguments - **Scientific Research and Clinical Studies**: Niagen has conducted 40 peer-reviewed clinical studies demonstrating the safety and efficacy of its product, particularly in age-related conditions [7][18][24] - **Unique Positioning**: Unlike many dietary supplement companies, Niagen is rooted in scientific research and intellectual property, which differentiates it from competitors that primarily engage in marketing [11][14][17] - **Regulatory Challenges**: The company faces strict regulations that prevent it from making health claims typically associated with drugs, which influences its marketing strategy [23][24] - **Market Strategy**: Niagen relies on word-of-mouth and expert endorsements rather than direct consumer claims to build trust and credibility [24][25] Recent Developments - **Product Launches**: The company launched the Niagen Plus line, which includes IV products and at-home injectables, generating significant media attention and interest from celebrities and influencers [34][35][40] - **Clinical Trials**: A phase three clinical study on Parkinson's disease with 400 participants is nearing completion, which could significantly impact the company's valuation and credibility in the biotech space [18][54] - **Financial Health**: Niagen is cash flow positive, has no debt, and does not require additional capital for its operations, which is atypical for biotech companies [52][54] Potential Risks and Concerns - **Market Competition**: The rise of fraudulent companies claiming to offer NAD products poses a risk to the overall market perception and could impact Niagen's reputation [27][29] - **Consumer Education**: There is a need to educate consumers about the differences between Niagen and other NAD products, particularly regarding bioavailability and efficacy [27][37] Future Outlook - **Injectable Products**: The company plans to introduce a self-injection product within the next year, tapping into the growing trend of self-administered health solutions [49][50] - **Pharmaceutical Opportunities**: Niagen is exploring drug indications beyond dietary supplements, which could enhance its market position and attract sophisticated investors [54] Conclusion - Niagen Bioscience is well-positioned in the NAD market with a strong scientific foundation, innovative products, and a clear strategy to navigate regulatory challenges while maintaining financial stability. The company's focus on research and quality sets it apart from competitors, and its future product developments could significantly expand its market reach and impact.

Company to Expand Patented Wellness Approach into High-Growth Cognitive and Restorative Sleep Markets, Emphasizing Scientific Rigor and Unique Formulations SCOTTSDALE, AZ, June 03, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or the “Company”), a wellness and dietary supplement company known for Sure Shot™, its patented product that rapidly lowers blood alcohol content by supporting its metabolism, today announced the initiation of research and development (R&D) for innovative ne ...

Board Initiates CEO Search Process Terrence Moorehead to Step Down as President and CEO, Once Successor Appointed Company Reaffirms Full Year 2025 Outlook LEHI, Utah, June 02, 2025 (GLOBE NEWSWIRE) -- Nature’s Sunshine Products, Inc. (Nasdaq: NATR) (“Nature’s Sunshine”) (the “Company”), a leading manufacturer of high-quality herbal and nutritional supplements, today announced that Terrence Moorehead has notified the Company’s Board of Directors (the “Board”) of his decision to step down as President and Chi ...

Core Viewpoint - Safety Shot, Inc. is holding its Annual Shareholders' Meeting on June 12, 2025, in a virtual format, emphasizing the importance of shareholder participation and voting [1][4]. Meeting Details - The meeting will commence at 11:00 AM EDT and requires prior registration for attendance [1]. - The record date for stockholders entitled to vote is April 28, 2025 [2]. Proxy Proposals - Several key proposals will be voted on during the meeting, including: 1. Approval of the issuance of Safety Shot Shares to Yerbaé Shareholders [5]. 2. Amendment to the Safety Shot 2024 equity incentive plan to increase the number of shares reserved for issuance [5]. 3. Authorization for the issuance of promissory notes and shares related to a securities offering completed on January 20, 2025 [5]. 4. Approval for the issuance of up to 20,000,000 Safety Shot Shares to Core 4 Capital Corp. in non-public offerings [5]. 5. Granting authority for a reverse stock split within a specified range [5]. 6. Proposal for adjournment of the meeting if necessary to solicit additional proxies [5]. Voting Information - Shareholders received a Notice of Internet Availability of Proxy Materials in early May, detailing how to access the Proxy Statement and annual report [3]. - Voting can be conducted via internet, telephone, or mail, with dedicated phone numbers provided for assistance [1][3]. Company Overview - Safety Shot, Inc. specializes in wellness and dietary supplements, with its flagship product, Sure Shot, designed to lower blood alcohol content while enhancing clarity and energy [5][6]. - The company plans to expand its business-to-business sales of Sure Shot to various distributors and retailers throughout 2025 [6].